STOCK TITAN

BrainStorm current liabilities reach $13.2M in Q3

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

BrainStorm Cell Therapeutics reported a third-quarter 2026 net loss of $1.733 million, compared with $2.106 million a year earlier; net loss per share was $0.14, versus $0.19. Operating loss was $1.615 million, compared with $2.047 million.

At September 30, 2026, cash and cash equivalents were $163,000 and current liabilities were $13.172 million, compared with $29,000 and $11.007 million, respectively, at December 31, 2025. The company said it was advancing and completing preparations to initiate the Phase 3b ENDURANCE study of NurOwn in ALS. Professor Peter J. Pitts was appointed Executive Chairman during the quarter and joined in an active executive capacity.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointQuarterly net loss narrowed to $1.733 million from $2.106 million.

Negative

  • None.

Filing Explained

The balance sheet reports 14,259,377 common shares issued and outstanding at September 30, 2026, up from 11,034,775 at December 31, 2025. For a holder whose share count stayed fixed, the larger outstanding base means a smaller proportional ownership stake.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net loss $1.733 million Three months ended September 30, 2026; compared with $2.106 million in the same period of 2025
Operating loss $1.615 million Three months ended September 30, 2026; compared with $2.047 million in the same period of 2025
Net loss per share $0.14 Three months ended September 30, 2026; compared with $0.19 in the same period of 2025
Research and development expense, net $523,000 Three months ended September 30, 2026; compared with $899,000 in the same period of 2025
General and administrative expense $1.092 million Three months ended September 30, 2026; compared with $1.148 million in the same period of 2025
Cash and cash equivalents $163,000 As of September 30, 2026; $29,000 as of December 31, 2025
Current liabilities $13.172 million As of September 30, 2026; $11.007 million as of December 31, 2025
Common shares issued and outstanding 14,259,377 shares As of September 30, 2026; 11,034,775 shares as of December 31, 2025
Special Protocol Assessment regulatory
"under a Special Protocol Assessment"
A special protocol assessment is a formal, written agreement between a drug or device developer and a health regulator about the design, size and analysis plans of a pivotal clinical trial or study. It matters to investors because it reduces regulatory uncertainty—like getting a signed blueprint before building—by signaling that if the study follows the agreed plan and meets its goals, the regulator is unlikely to reject the results solely for design reasons, though it does not guarantee approval.
autologous MSC-NTF cells medical
"The NurOwn® technology platform (autologous MSC-NTF cells)"
neurotrophic factors medical
"secrete high levels of neurotrophic factors (NTFs)"
Orphan Drug designation regulatory
"has received Orphan Drug designation"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Floor Effect medical
"a comprehensive analysis of the “Floor Effect”"
ex vivo technical
"expanded and differentiated ex vivo"
Ex vivo describes tests or treatments performed on living cells, tissues, or organs that have been removed from the body and studied in an external environment. For investors, ex vivo work sits between basic lab dish tests and whole‑animal or human studies, offering a more realistic preview of how a therapy or diagnostic might behave in real tissue — like running an engine on a test stand before putting it back into a car — which can reduce scientific risk and inform development milestones.
Net loss $1.733 million Compared with $2.106 million in the third quarter of 2025
Operating loss $1.615 million Compared with $2.047 million in the third quarter of 2025
Net loss per share $0.14 Compared with $0.19 in the third quarter of 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was BCLI's net loss in the third quarter of 2026?

BrainStorm reported a $1.733 million net loss for the third quarter ended September 30, 2026, compared with $2.106 million in the same quarter of 2025.

What supports BCLI's planned Phase 3b ENDURANCE study?

BrainStorm said the study is supported by an FDA-agreed protocol under a Special Protocol Assessment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001137883 0001137883 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36641   20-7273918
(State or other jurisdiction of
incorporation)
  (Commission File No.)   (IRS Employer Identification No.)

 

1325 Avenue of Americas, 28th Floor  
New York, NY 10019
(Address of principal executive offices) (Zip Code)

 

(201) 488-0460

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
     

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 16, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is being furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.  Description
99.1  Press Release issued by Brainstorm Cell Therapeutics Inc. on November 16, 2026.
104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BRAINSTORM CELL THERAPEUTICS INC.
     
Date: November 16, 2026 By: /s/ Chaim Lebovits
    Chaim Lebovits
    President and Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

 

NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a corporate update.

 

“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options,” said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. “We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment. During the third quarter, we strengthened our leadership with the appointment of Professor Peter J. Pitts as Executive Chairman and broadened our engagement with regulators, potential commercial partners, and investors. Professor Pitts has joined the Company in an active executive capacity and is helping lead the regulatory, operational, partnership, and capital-markets initiatives surrounding the NurOwn program. His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this important next phase, and we remain resolute in our commitment to advancing what we believe will be a valuable new therapeutic option for the ALS community.”

 

Recent Highlights

 

Clinical, Scientific, and Regulatory Progress

 

·Advancing Phase 3b ENDURANCE Readiness & Constructive Regulatory Backdrop. BrainStorm continues to execute on operational, clinical, and manufacturing activities to support the initiation of the Phase 3b ENDURANCE study of NurOwn® (MSC-NTF cells) in earlier-stage ALS patients under its FDA-agreed Special Protocol Assessment (SPA). The Company also notes the FDA’s October 2026 launch of its Rare Disease Framework Initiative, aimed at establishing a more holistic, fit-for-purpose regulatory framework for rare diseases with severe unmet medical needs.

 

·Peer-Reviewed Publication on NurOwn®-Derived Extracellular Vesicles (ExMN). BrainStorm’s R&D team published “Beneficial effects of small extracellular vesicles derived from MSC-NTF (NurOwn®) cells on lung inflammation and fibrosis” in Stem Cell Research & Therapy, a Q1-ranked journal (DOI: 10.1186/s13287-026-05303-y). The study demonstrated reduced lung inflammation and fibrosis, improved oxygenation, and protection against subsequent lung injury following inhaled pretreatment in preclinical models, supporting the therapeutic and preventive potential of NurOwn®-Derived Extracellular Vesicles (ExMN).

 

Corporate and Leadership

 

·Appointed Professor Peter J. Pitts as Executive Chairman. On July 28, 2026, BrainStorm announced the appointment of Professor Peter J. Pitts, a former FDA Associate Commissioner and co-founder of the Center for Medicine in the Public Interest, as Executive Chairman and Chief Strategic Regulatory and Policy Officer. Professor Pitts, who joined the Board in May 2026, leads the Company’s daily operations, partnerships, investor engagement, and regulatory strategy, focused primarily on advancing the Phase 3b ENDURANCE trial. Professor Jacob Frenkel, a member of BrainStorm’s leadership team since 2007 and Board Chairman since 2020, transitioned to Senior Advisor.

 

 

 

 

Industry and Investor Engagement

 

·Participated in DUPHAT 2026 in Dubai. In August 2026, CEO Chaim Lebovits and Executive Chairman Professor Peter J. Pitts participated in the 31st Dubai International Pharmaceuticals & Technologies Conference and Exhibition (DUPHAT) at the Dubai World Trade Centre. Professor Pitts delivered keynote addresses and moderated panel sessions on regulatory science harmonization and translational collaboration, while BrainStorm’s leadership met with regional health regulators, commercial distribution partners, and international investment groups regarding the strategic positioning of NurOwn® and the planned Phase 3b ENDURANCE trial.

 

Financial Results for the Third Quarter Ended September 30, 2026

 

·Cash, cash equivalents, and restricted cash were approximately $0.35 million as of September 30, 2026, compared to approximately $0.24 million as of September 30, 2025.

 

·Research and development expenditures, net, for the third quarter of 2026 were approximately $0.5 million, compared to approximately $0.9 million for the third quarter of 2025.

 

·General and administrative expenses for the third quarter of 2026 were approximately $1.09 million, compared to approximately $1.15 million for the third quarter of 2025.

 

·Net loss for the third quarter of 2026 was approximately $1.7 million, compared to a net loss of approximately $2.1 million for the third quarter of 2025.

 

·Net loss per share for the third quarters of 2026 and 2025 was $(0.14) and $(0.19), respectively.

 

 

 

 

U.S. dollars in thousands

(Except share and per share amounts)

 

   September 30,   December 31, 
   2026   2025 
   Unaudited   Audited 
   U.S. $ in thousands 
ASSETS          
           
Current Assets:          
Cash and cash equivalents  $163   $29 
Other accounts receivable   189    86 
Prepaid expenses and other current assets   101    192 
Total current assets  $453   $307 
           
Long-Term Assets:          
Prepaid expenses and other long-term assets  $26   $25 
Restricted Cash   185    247 
Right of use asset   53    208 
Property and equipment, net   123    235 
Total Long-Term Assets  $387   $715 
           
Total assets  $840   $1,022 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current Liabilities:          
Accounts payable  $7,473   $7,067 
Accrued expenses   464    396 
Short-term loans   1,875    967 
Operating lease liability   56    208 
Employees related liability   3,304    2,369 
Total current liabilities  $13,172   $11,007 
           
Total liabilities  $13,172   $11,007 
           
Stockholders’ Deficit:          
Stock capital:   16    16 
Common stock $0.00005 par value; 250,000,000 shares authorized at September 30, 2026 and December 31, 2025; 14,259,377 and 11,034,775 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively          
Additional paid-in-capital   232,426    227,058 
Treasury stock   (116)   (116)
Accumulated deficit   (244,658)   (236,943)
Total stockholders’ deficit  $(12,332)  $(9,985)
           
Total liabilities and stockholders’ deficit  $840   $1,022 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 

 

 

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

 

U.S. dollars in thousands

(Except share and per share amounts)

 

   Nine months ended   Three months ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
   Unaudited   Unaudited 
Operating expenses:                    
                     
Research and development, net  $2,248   $3,323   $523   $899 
General and administrative   5,026    4,386    1,092    1,148 
                     
Operating loss   (7,274)   (7,709)   (1,615)   (2,047)
                     
Financial income (expense), net   (441)   (343)   (118)   (59)
                     
Gain (loss) on change in fair value of Warrants liability   -    179    -    - 
                     
Net loss  $(7,715)  $(7,873)  $(1,733)  $(2,106)
                     
Basic and diluted net loss per share from continuing operations  $(0.68)  $(0.91)  $(0.14)  $(0.19)
                     
Weighted average number of shares outstanding used in computing basic and diluted net loss per share   11,354,405    8,673,908    11,983,241    11,008,047 

 

 

 

 

About NurOwn®

 

The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

 

About BrainStorm Cell Therapeutics Inc.

 

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.

 

NurOwn® is BrainStorm’s lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the “Floor Effect,” a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm’s growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.

 

 

 

 

Notice Regarding Forward-Looking Statements

 

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), the Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management’s ability to successfully achieve its goals, BrainStorm’s ability to raise additional capital, BrainStorm’s ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm’s future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm’s annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. BrainStorm does not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although BrainStorm believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements.

 

CONTACTS

 

Investors:

Michael Wood

Phone: +1 646-597-6983

mwood@lifesciadvisors.com

 

Media:

Uri Yablonka, Chief Business Officer

Phone: +1 917-284-2911

uri@brainstorm-cell.com

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading